Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4115 Neoadjuvant PRRT with 90Y-DOTATOC: Preliminary results from a monocentric perspective study

Introduction: Surgery is considered the only curative treatment for pancreatic neuroendocrine tumors (pNETs), but it is feasible only in a few patients. A new possible strategy in pNETs is preoperative PRRT, as its cytoreductive effect could increase the efficacy of surgery.

Conference:

Presenting Author:

Authors: Barone A, Grana C, Papi S, Bertani E, Rocca P,

Keywords: PRRT, 90Y-DOTATOC, Neoadjuvant PRRT, pancreatic NET,

#3733 New insights on the clinical role of Ki-67 and spindle cell and oncocytic histological variants in lung carcinoid tumors

Introduction: WHO classification defines lung carcinoid tumors (LCTs) as well-differentiated neuroendocrine neoplasms classified in typical (TC) and atypical carcinoids (AC). Morphologic factors and protein expression able to predict recurrence after surgical curative resection are little known. Ki-67 and spindle cell and oncocytic histological variants may impact on differential diagnosis, but their clinical relevance is much debated.

Conference:

Presenting Author: Milione M

Authors: Centonze G, Maisonneuve P, Grillo F, Prinzi N, Lagano V,

Keywords: lung carcinoid, Ki-67, spindle cell, oncocytic, Immunohistochemistry,

#3707 Neoadjuvant PRRT with Y-90-DOTATOC – Preliminary results from a monocentric prospective study

Introduction: Surgery is considered the only curative option in pNET but is feasible only in a minority of patients. A new possible therapeutical strategy in pNETs is preoperative Peptide Receptor Radionuclide Therapy (PRRT) in order to increase the efficacy of surgery.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Bertani E, Cascio A, Rocca P,

Keywords: PRRT, Y-90-Dotatoc, Neoadjuvant PRRT, pancreatic NET,

#3543 Safety of Lanreotide Autogel (LAN) 120 mg plus Metformin (MET) in patients with advanced, well-differentiated (WD) gastro-intestinal (GI) or lung neuroendocrine tumors (NETs) - A pilot, open-label, prospective study: The MetNET-2 Trial (NCT02823691)

Introduction: Preclinical and clinical evidence supports a potential role for MET as an antineoplastic agent in WD NETs.

Conference:

Presenting Author: Pusceddu S

Authors: Pusceddu S, Prinzi N, Corti F, Beninato T, Milione M,

Keywords: neuroendocrine tumor, metformin, somatostatin analogues,

#3497 Activity and safety of metformin (MET), Everolimus (EVE) and Octreotide (OCT) in patients (pts) with advanced, well-differentiated (WD) pancreatic neuroendocrine tumors (pNETs). The prospective phase II MetNET-1 trial (NCT02294006). Interim analysis

Introduction: Preclinical and clinical evidences support a role for metformin as an antineoplastic agent in WD pNETs.

Conference:

Presenting Author: Pusceddu S

Authors: Pusceddu S, Prinzi N, Corti F, Beninato T, Milione M,

Keywords: pancreatic NET, metformin, somatostatin analogues, everolimus,